What happened
FMR LLC, a 10% owner of Avalyn Pharma Inc. (NASDAQ: AVLN), sold 228,454 shares of common stock on Nov. 9 and 10. OptimistFi calculates that the sale equals 10.0% of the 2,284,535 shares FMR held before the trade.
The sales brought in about $6.70 million. The Form 4 lists four transactions. On Nov. 9, FMR sold 173,661 shares at $29.06 and 1,339 shares at $29.75. On Nov. 10, it sold 5,565 shares at $29.56 and 47,889 shares at $30.28. Each price is a weighted average of several trades, the filing says. The underlying trades ranged from $28.65 to $30.62.
After the sales, FMR reported 2,056,081 shares, held indirectly through F-Prime Capital Partners Healthcare Fund V LP. The general partner of that fund is F-Prime Capital Partners Healthcare Advisors Fund V LP, which is managed by Impresa Management LLC.
The filing, signed Nov. 12, identifies Abigail P. Johnson as a director, chairman and chief executive of FMR LLC. It says it is not an admission that the reporting parties are beneficial owners of the securities reported.
Explain the financial terms
A Form 4 is the SEC report an officer, director or 10% owner files within two business days of buying or selling the company's stock.
Why it matters
OptimistFi has argued that Avalyn's equity works only if its drug-development programs reach value-creating data before financing dilution absorbs the upside. One large holder's trim leaves that case unchanged.
The trade trimmed the position rather than closing it, so most of FMR's stake remains in place. It reads as a partial reduction by one investor, not a verdict on the company's programs.
The selling came in four separate lines over two days, and each price is a weighted average of several trades. The remaining shares stay held indirectly through the F-Prime fund, so the filing shows a stepwise reduction of an existing position, not a single block exit.
What's next
The next scheduled test is Avalyn's next quarterly report. OptimistFi will look there for the cash balance, any new share issuance and progress on the drug programs.
A cash position that carries the programs without new issuance would ease the dilution risk in OptimistFi's case, while fresh financing would raise it.